KIT and intrahepatic cholangiocarcinoma: In the 2022 ICC, myeloid neoplasms are the exclusive related hematologic conditions due to their shared KIT mutations and clonal abnormalities with SM, distinguishing them from lymphoid neoplasms that co-occur with SM but lack KIT mutations [67,68].